103 related articles for article (PubMed ID: 2136818)
1. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
Thomas M; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
[TBL] [Abstract][Full Text] [Related]
2. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568
[TBL] [Abstract][Full Text] [Related]
3. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
4. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
6. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
9. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin.
Lumley P; Keery RJ; Wharton KA; White BP; Watts IS
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():603-6. PubMed ID: 1825385
[No Abstract] [Full Text] [Related]
10. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo.
Watts IS; White BP; Wharton KA; Lumley P
Br J Pharmacol; 1989 Dec; 98 Suppl():842P. PubMed ID: 2611538
[No Abstract] [Full Text] [Related]
11. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction.
Beasley RC; Featherstone RL; Church MK; Rafferty P; Varley JG; Harris A; Robinson C; Holgate ST
J Appl Physiol (1985); 1989 Apr; 66(4):1685-93. PubMed ID: 2525122
[TBL] [Abstract][Full Text] [Related]
12. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems.
Takahara K; Murray R; FitzGerald GA; Fitzgerald DJ
J Biol Chem; 1990 Apr; 265(12):6836-44. PubMed ID: 2139029
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
14. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood.
Heptinstall S; May JA; Glenn JR; Sanderson HM; Dickinson JP; Wilcox RG
Thromb Haemost; 1995 Nov; 74(5):1310-5. PubMed ID: 8607115
[TBL] [Abstract][Full Text] [Related]
15. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
16. Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man.
Ritter JM; Benjamin N; Doktor HS; Barrow SE; Mant TG; Schey S; Stewart-Long P
Br J Clin Pharmacol; 1990 Apr; 29(4):431-6. PubMed ID: 2139338
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
18. Modulation by adenosine of thromboxane A2 receptor-mediated constriction in the human umbilical artery.
Di Grande A; Malatino LS; Boura AL; Read MA; Walters WA
Int J Clin Pharmacol Ther; 1994 Jul; 32(7):344-6. PubMed ID: 7952795
[TBL] [Abstract][Full Text] [Related]
19. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
